TiGenix confirms strategic focus on Cx601 and its adipose derived stem cell (eASC) platform – Nasdaq
|
TiGenix confirms strategic focus on Cx601 and its adipose derived stem cell (eASC) platform
Nasdaq Leuven (BELGIUM) – December 20, 2017, 7:00h CET – TiGenix NV (Euronext Brussels and NASDAQ:TIG) ("TiGenix" or "the Company"), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived … |
